GLP SAM-Screener™ Assay Kit

Territorial Availability: Available through Bertin Technologies only in France

• Correlated keywords
  • kits assays measures measurements G9a like proteins alterations chromatins structures posttranslational post-translational modifications histones regulatory steps DNA deoxyribonucleic acids lysines methylations central roles epigenetics genomes Dot1 methyltransferases conserved domains SET S-adenosyl-L-methionines AdoMet co-factors cofactors catalyzes epsilons amino group domains domain-containing mono-methylates di-methylates H3 9 H3K9 sequences identity indentities euchromatic H3K9me1 H3K9me2 enzymes nonhistones substrates p53(K372) humans recombinants N-terminal N-terminus truncation residues 1,004-1,298 1004-1298 fluorescence polarizations FP small molecules fluorescent probes binding pockets endogenous inhibitor inhibits inhibition sinefungin peptides high-throughput screening HTS SAM screeners genes regulations chromatin drugs
• Product Overview:
  Most histone lysine methyltransferases contain a conserved domain (SET) that utilizes S-adenosyl-L-methionine (SAM or AdoMet) as a co-factor to catalyze the methylation of the epsilon amino group of lysine. G9a-like protein (GLP) is a SET domain-containing methyltransferase that specifically mono- and di-methylates histone H3 at lysine 9 (H3K9). GLP and G9a function as major euchromatic H3K9me1 and H3K9me2 histone methyltransferases and also have been found to methylate several nonhistone substrates, including p53(K372). This fluorescence polarization assay is based upon a proprietary small molecule fluorescent probe* that binds to the SAM binding pocket in GLP. Binding of the small molecule probe to GLP induces an increase in fluorescence polarization. Binding of the probe can be competed with the endogenous cofactor SAM or by the inhibitor sinefungin, but is unaffected by the histone H3 peptide substrate. The GLP SAM-Screener™ Assay is robust (Z’ >0.5) and exhibits a greater than 100 mP shift over a range of 0-250 nM GLP. The assay is suitable for high-throughput screening in the provided 384-well plate or can be scaled to higher density plate formats (e.g., 1,536-well) if desired. *United States Patent 9,120,820